The evaluation and management of shock

Clinics in Chest Medicine

Volumn 24, Issue 4, 2003, Pages 775-789

  Holmes, Cheryl L ^a   Walley, Keith R ^b  

^a KELOWNA GENERAL HOSPITAL   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ACTIVATED PROTEIN C; ADRENALIN; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; AMRINONE; ANTIBIOTIC AGENT; ANTIINFLAMMATORY AGENT; BICARBONATE; CORTICOSTEROID; CORTICOTROPIN; DOBUTAMINE; DROTRECOGIN; FLUDROCORTISONE ACETATE; HYDROCORTISONE; INOTROPIC AGENT; ISOPRENALINE; MILRINONE; NORADRENALIN; PHENYLEPHRINE; PHOSPHODIESTERASE INHIBITOR; VASOACTIVE AGENT; VASOPRESSIN;

BLEEDING; CARDIOGENIC SHOCK; CLINICAL EXAMINATION; CLINICAL FEATURE; CLINICAL TRIAL; DISEASE ACTIVITY; DISEASE CLASSIFICATION; HEART INFARCTION; HEMODYNAMIC MONITORING; HUMAN; HYPOVOLEMIC SHOCK; LACTIC ACIDOSIS; MULTIPLE ORGAN FAILURE; NONHUMAN; PRIORITY JOURNAL; RESUSCITATION; REVIEW; SEPTIC SHOCK; SHOCK; TREATMENT OUTCOME; VASODILATATION;

EID: 0346993075     PISSN: 02725231     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0272-5231(03)00107-2     Document Type: Review

References (56)

1. Collard CD, Gelman S. Pathophysiology, clinical manifestations, and prevention of ischemia-reperfusion injury. Anesthesiology 2001;94(6):1133-8.
2. Moore FA, Moore EE, Read RA. Postinjury multiple organ failure: role of extrathoracic injury and sepsis in adult respiratory distress syndrome. New Horiz 1993;1(4):538-49.
3. Papathanassoglou ED, Moynihan JA, Ackerman MH. Does programmed cell death (apoptosis) play a role in the development of multiple organ dysfunction in critically ill patients? A review and a theoretical framework. Crit Care Med 2000;28(2):537-49.
4. Hussain SN, Roussos C. Distribution of respiratory muscle and organ blood flow during endotoxic shock in dogs. J Appl Physiol 1985;59(6):1802-8.
5. Alderson P, Schierhout G, Roberts I, et al. Colloids versus crystalloids for fluid resuscitation in critically ill patients. Cochrane Database Syst Rev 2000;2:CD000567.
6. Meier-Hellmann A, Reinhart K, Bredle DL, et al. Epinephrine impairs splanchnic perfusion in septic shock. Crit Care Med 1997;25(3):399-404.
7. Sautner T, Wessely C, Riegler M, et al. Early effects of catecholamine therapy on mucosal integrity, intestinal blood flow, and oxygen metabolism in porcine endotoxin shock. Ann Surg 1998;228(2):239-48.
8. Nasraway SA. Norepinephrine: no more "leave 'em dead"? Crit Care Med 2000;28(8):3096-8.
9. Holmes Jr DR, Califf RM, Topol EJ. Lessons we have learned from the GUSTO trial. Global utilization of streptokinase and tissue plasminogen activator for occluded arteries. J Am Coll Cardiol 1995;25(7 Suppl): 10S-7.
10. Wood KE. Major pulmonary embolism: review of a pathophysiologic approach to the golden hour of hemodynamically significant pulmonary embolism. Chest 2002;121(3):877-905.
11. Rivers E, Nguyen B, Havstad S, et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001;345(19):1368-77.
12. Kem JW, Shoemaker WC. Meta-analysis of hemodynamic optimization in high-risk patients. Crit Care Med 2002;30(8):1686-92.
13. Rivers EP, Ander DS, Powell D. Central venous oxygen saturation monitoring in the critically ill patient. Curr Opin Crit Care 2001;7(3):204-11.
14. Ivatury RR, Sugerman HJ, Peitzman AB. Abdominal compartment syndrome: recognition and management. Adv Surg 2001;35:251-69.
15. Claussen MS, Landercasper J, Cogbill TH. Acute adrenal insufficiency presenting as shock after trauma and surgery: three cases and review of the literature. J Trauma 1992;32(1):94-100.
16. Rusnak RA. Adrenal and pituitary emergencies. Emerg Med Clin N Am 1989;7(4):903-25.
17. Annane D, Sebille V, Troche G, et al. A 3-level prognostic classification in septic shock based on cortisol levels and cortisol response to corticotropin. JAMA 2000;283(8):1038-45.
18. Gavin LA. Thyroid crises. Med Clin N Am 1991;75(1): 179-93.
19. Bravo EL. Pheochromocytoma. Cardiol Rev 2002;10(1):44-50.
20. Orlinsky M, Shoemaker W, Reis ED, et al. Current controversies in shock and resuscitation. Surg Clin North Am 2001;81(6):1217-62.
21. Stern SA. Low-volume fluid resuscitation for presumed hemorrhagic shock: helpful or harmful? Curr Opin Crit Care 2001;7(6):422-30.
22. Committee on Trauma. Advanced trauma life support program for physicians: instructor manual. Chicago: American College of Surgeons; 1993. p. 75-110.
23. Wiggers CJ. Experimental hemorrhagic shock. In: Physiology of shock. New York: Commonwealth Fund; 1950. p. 121-46.
24. Dillon J, Lynch Jr LJ, Myers R, et al. The treatment of hemorrhagic shock. Surg Gynecol Obstet 1966;122(5): 967-78.
25. Bickell WH, Bruttig SP, Millnamow GA, et al. The detrimental effects of intravenous crystalloid after aortotomy in swine. Surgery 1991;110(3):529-36.
26. Kaweski SM, Sise MJ, Virgilio RW. The effect of prehospital fluids on survival in trauma patients. J Trauma 1990;30(10):1215-8 [discussion 1218-9].
27. Bickell WH, Wall Jr MJ, Pepe PE, et al. Immediate versus delayed fluid resuscitation for hypotensive patients with penetrating torso injuries. N Engl J Med 1994;331(17):1105-9.
28. Siegel JH, Veech RL, Lessard MR, et al. Immediate versus delayed fluid resuscitation in patients with trauma. N Engl J Med 1995;332(10):681-3.
29. Smail N, Wang P, Cioffi WG, et al. Resuscitation after uncontrolled venous hemorrhage: does increased resuscitation volume improve regional perfusion? J Trauma 1998;44(4):701-8.
30. Goldberg RJ, Gore JM, Alpert JS, et al. Cardiogenic shock after acute myocardial infarction, Incidence and mortality from a community-wide perspective, 1975 to 1988. N Engl J Med 1991;325(16):1117-22.
31. Camendran L, Abboud R, Sleeper LA, et al. Trends in cardiogenic shock: report from the SHOCK Study. The should we emergently revascularize occluded coronaries for cardiogenic shock? Eur Heart J 2001;22(6): 472-8.
32. Hollenberg SM, Kavinsky CJ, Parrillo JE. Cardiogenic shock. Ann Intern Med 1999;131(1):47-59.
33. Col NF, Gurwitz JH, Alpert JS, et al. Frequency of inclusion of patients with cardiogenic shock in trials of thrombolytic therapy. Am J Cardiol 1994;73(2): 149-57.
34. Hochman JS, Sleeper LA, Webb JG, et al. Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK Investigators. Should we emergently revascularize occluded coronaries for cardiogenic shock. N Engl J Med 1999;341(9): 625-34.
35. Hochman JS, Sleeper LA, White HD, et al. One-year survival following early revascularization for cardiogenic shock. JAMA 2001;285(2):190-2.
36. ACCP/SCCM. American College of Chest Physicians/ Society of critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992;20(6):864-74.
37. Levy MM, Fink MP, Marshall JC, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 2003;31(4):1250-6.
38. Friedman G, Silva E, Vincent JL. Has the mortality of septic shock changed with time? Crit Care Med 1998;26(12):2078-86.
39. Cronin L, Cook DJ, Carlet J, et al. Corticosteroid treatment for sepsis: a critical appraisal and meta-analysis of the literature. Crit Care Med 1995;23(8):1430-9.
40. Annane D. Corticosteroids for septic shock. Crit Care Med 2001;29(7 Suppl):S117-20.
41. Marik PE, Zaloga GP. Adrenal insufficiency during septic shock. Crit Care Med 2003;31(1):141-5.
42. Keh D, Boehnke T, Weber-Cartens S, et al. Immunologic and hemodynamic effects of "low-dose" hydrocortisone in septic shock: a double-blind, randomized, placebo-controlled, crossover study. Am J Respir Crit Care Med 2003;167(4):512-20.
43. Streeten DHP. What test for hypothalamic-pituitary adrenocortical insufficiency? Lancet 1999;354:179-80.
44. Annane D, Sebille V, Charpentier C, et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 2002;288(7):862-71.
45. Matthay MA. Severe sepsis-a new treatment with both anticoagulant and antiinflammatory properties. N Engl J Med 2001;344(10):759-62.
46. Bemard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001;344(10):699-709.
47. Morris PE, Light RB, Garber GE. Identifying patients with severe sepsis who should not be treated with drotrecogin alfa (activated). Am J Surg 2002;184(6 Suppl): S19-24.
48. Garber G, Gibney RTN, Light RB, et al. Guidance on patient identification and administration of human recombinant activated protein C for the treatment of severe sepsis. Can J Infect Dis 2002;13(6):361-72.
49. Manns BJ, Lee H, Doig CJ, et al. An economic evaluation of activated protein C treatment for severe sepsis. N Engl J Med 2002;347(13):993-1000.
50. Holmes CL, Patel BM, Russell JA, et al. Physiology of vasopressin relevant to management of septic shock. Chest 2001;120(3):989-1002.
51. Patel BM, Chittock DR, Russell JA, et al. Beneficial effects of short-term vasopressin infusion during severe septic shock. Anesthesiology 2002;96(3):576-82.
52. Holmes CL, Russell JA, Walley KR. Sepsis: is there room for vasopressin? Sepsis 2001;4:169-75.
53. Forsythe SM, Schmidt GA. Sodium bicarbonate for the treatment of lactic acidosis. Chest 2000;117(1):260-7.
54. Cooper DJ, Walley KR, Wiggs BR, et al. Bicarbonate does not improve hemodynamics in critically ill patients who have lactic acidosis. A prospective, controlled clinical study. Ann Intern Med 1990;112(7):492-8.
55. Mathieu D, Neviere R, Billard V, et al. Effects of bicarbonate therapy on hemodynamics and tissue oxygenation in patients with lactic acidosis: a prospective, controlled clinical study. Crit Care Med 1991;19(11):1352-6.
56. Landry DW, Oliver JA. The pathogenesis of vasodilatory shock. N Engl J Med 2001;345(8):588-95.